<span item_type="fundamental" item_id="6d0a15688bcfb69c515ba58ea4a9ea7d" counter_id="ST/US/RVPHW" env="prod"></span><span item_type="announcement" item_id="516467576897343105" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.13.</p><p></p><h3>Segment Revenue</h3><ul><li>The company did not report any revenue as it is a clinical-stage biopharmaceutical company and has not generated any revenues from the sale of products.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The net loss for the three months ended March 31, 2025, was $6.4 million, compared to $7.4 million for the same period in 2024, representing a decrease of 13.5%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm"></span></li><li><strong>Research and Development Expenses</strong>: These expenses were approximately $4.1 million for the three months ended March 31, 2025, a decrease from $5.8 million in the same period in 2024, primarily due to decreased external clinical research and development costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm"></span></li><li><strong>General and Administrative Expenses</strong>: These expenses increased to approximately $2.4 million for the three months ended March 31, 2025, from $2.1 million in the same period in 2024, mainly due to increased stock-based compensation expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the three months ended March 31, 2025, net cash used in operating activities was approximately $8.2 million, compared to $11.7 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: Approximately $7.3 thousand was provided by financing activities for the three months ended March 31, 2025, primarily from the exercise of common stock warrants.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Warrant Liabilities</strong>: The company recognized a gain on the remeasurement of warrant liabilities of approximately $0.1 million for the three months ended March 31, 2025, compared to $0.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue the clinical development of its lead drug candidate, brilaroxazine, for the treatment of schizophrenia and other indications, subject to additional financing. The company expects to initiate the registrational RECOVER-2 Trial in mid-2025, with topline readout anticipated in the third quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company may advance the development of its second drug candidate, RP1208, for the treatment of depression and obesity, subject to additional financing.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm"></span></li><li><strong>Priority</strong>: The company emphasizes the completion of the clinical development of brilaroxazine for acute and maintenance schizophrenia as its primary focus.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1742927/000143774925017191/rvph20250331_10q.htm"></span></li></ul>

Reviva Pharmaceuticals - CW23 | 10-Q: FY2025 Q1 EPS: USD -0.13